Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
BACKGROUND
Estrogen deprivation therapy for myoma/adenomyosis decreases bone mineral density and can only be applied in the short term, as temporizing measures in the premenopausal woman.


OBJECTIVE
To examine the effects of bisphosphonate minodronic acid on markers of bone turnover over a 6-month period in women receiving gonadotropin-releasing hormone agonist (GnRHa).


METHODS
We retrospectively analyzed the medical records of 19 premenopausal patients with myoma/adenomyosis, who received GnRHa (leuprolide acetate, 1.88 mg/month or buserelin acetate, 900 µg/day) for 6 months from January 2014 to December 2014. Eight patients concomitantly received minodronic acid 50 mg every month during GnRHa therapy, and 11 treated with GnRHa alone. To compare these data in a case-controlled study, we analyzed an age-matched group of seven (premature or natural) menopausal women treated with minodronic acid. The primary outcome was percent changes in bone turnover markers in urine at 6 months.


RESULTS
In menopausal women group, minodronic acid (50 mg once-monthly) for 6 months decreased urinary deoxypyridinoline (DPD) and cross-linked N-telopeptides of type 1 collagen (NTX). Women receiving a GnRHa had a significant increase in urinary DPD and TNX at 6 months while minodronic acid during GnRHa therapy improved urinary levels of DPD and NTX to near baseline.


CONCLUSION
Minodronic acid treatment appears to be promising in women with secondary bone loss receiving GnRHa treatment.
['Imai|Atsushi|A|', 'Matsunami|Kazutoshi|K|', 'Ichigo|Satoshi|S|', 'Takagi|Hiroshi|H|']
D062788:Adenomyosis D000328:Adult D015415:Biomarkers D016723:Bone Remodeling D001862:Bone Resorption D002064:Buserelin D004164:Diphosphonates D005260:Female D007987:Gonadotropin-Releasing Hormone D006801:Humans D007093:Imidazoles D007889:Leiomyoma D016729:Leuprolide D008875:Middle Aged D010865:Pilot Projects D012189:Retrospective Studies D014594:Uterine Neoplasms
minodronic acid Bisphosphonate bone turnover markers GnRHa-induced bone loss